Becton Dickinson and Co (BDX) has hit a 5-day low amid a broader market trend where the Nasdaq-100 is up 0.25% and the S&P 500 is up 0.01%.
The company recently announced a collaboration with Ypsomed to develop a 5.5mL syringe aimed at enhancing self-administration efficiency for patients. This product innovation is expected to meet the growing demand for large-volume subcutaneous injections, featuring an 8mm short needle and thinner wall cannulas to improve injection times and optimize flow. The partnership is poised to drive market growth in high-dose biopharmaceuticals, with syringe samples expected by mid-2026.
This collaboration highlights BDX's commitment to addressing patient needs in the high-dose biologics space, potentially positioning the company favorably in a competitive market.
Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 201.920
Low
183.00
Averages
202.38
High
220.00
Current: 201.920
Low
183.00
Averages
202.38
High
220.00
Piper Sandler
Jason Bednar
Neutral
maintain
$190 -> $205
2026-01-28
New
Reason
Piper Sandler
Jason Bednar
Price Target
$190 -> $205
AI Analysis
2026-01-28
New
maintain
Neutral
Reason
Piper Sandler analyst Jason Bednar raised the firm's price target on Becton Dickinson (BDX) to $205 from $190 and keeps a Neutral rating on the shares. The firm notes the company changed its business unit reporting methodology beginning Q1-26, and Piper is updating its model to reflect that new approach. Note that the firm's estimates continue to include the Life Sciences unit, which is finding a new home with Waters (WAT) in a couple weeks.
Stifel
NULL
to
Buy
maintain
$210 -> $215
2026-01-07
Reason
Stifel
Price Target
$210 -> $215
2026-01-07
maintain
NULL
to
Buy
Reason
Stifel raised the firm's price target on Becton Dickinson (BDX) to $215 from $210 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is constructive for large-cap MedTech following 2025 pressures, adjusted targets among its coverage and highlights Boston Scientific (BSX), Edwards Lifesciences (EW), and Solventum (SOLV) as its three top ideas entering the year.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDX
Unlock Now
BofA
Travis Steed
Neutral
maintain
$190 -> $207
2026-01-05
Reason
BofA
Travis Steed
Price Target
$190 -> $207
2026-01-05
maintain
Neutral
Reason
BofA analyst Travis Steed raised the firm's price target on Becton Dickinson to $207 from $190 and keeps a Neutral rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.
RBC Capital
Sector Perform
maintain
$202 -> $210
2025-12-17
Reason
RBC Capital
Price Target
$202 -> $210
2025-12-17
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Becton Dickinson to $210 from $202 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it is positioned to grow mid-single-digits due to its strong durable core with high recurring revenue.
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
